Companiile Moderna și Merck au anunțat, miercuri, primele rezultate promițătoare în ultima fază a studiilor clinice privind vaccinul lor experimental pe bază de ARN mesager împotriva cancerului de piele

Moderna and Merck announced promising results from a clinical trial of their mRNA-based skin cancer vaccine, showing potential to delay cancer recurrence in high-risk melanoma patients. The study involved 1,137 patients who had undergone surgery for melanoma. The experimental vaccine, Intismeran, was used alongside Merck's Keytruda immunotherapy. This marks a significant advancement in cancer treatment research, with plans to present further data at an upcoming medical conference.